IMNR – The Immune Response Corporation — StockGuru Profile IMNR
The Immune Response Corporation (OTCBB:IMNR), is an immuno-pharmaceutical company. Stock Guru has scheduled several interviews with IMNR’s scientists and officers. But before we present those interviews we’d like to bring you up to date to the activities of Immune Response Corporation.
IMNR proceeded to accelerate the development of their most promising immune-based therapies.
The first is known as NeuroVax(TM) and is in development for multiple sclerosis (MS).
The second is known as IR103 and is in development for HIV/AIDS.
Joseph O’Neill, MD, MPh Chief Executive Officer and President has now been with the company for one year. He came to IMNR from the White House to join IRC where he was Director of the White House Office of National AIDS Policy. He is a poised and serious CEO. He is an MD and a graduate of the School of Medicine of the University of California at San Francisco, Dr. O’Neill also holds degrees in business administration, public health, health and medical sciences from the University of California at Berkeley. He is board certified in internal medicine.
We will take a look at the activities of the company including an upcoming presentation at the prestigous and important Rodman Healthcare Conference on November 7, 2006. The Rodman & Renshaw 8th Annual Healthcare Conference will be held at the New York Palace Hotel, New York, NY and we will update you as soon as their presentation is made.
Let’s take a look at the events of the last year for IMNR. This information comes from the President’s Annual Letter regarding the company. It is available online at http://www.imnr.com/ir/ir.htm.
Despite our conviction and our progress, we remain frustrated by the performance of our stock and believe our share price does not nearly reflect the current and potential value of our company. This gap in value is, of course, the crux of the opportunity for investors that have recently purchased our stock or are considering doing so in the near future. We intend to continue to execute our clinical, commercial and communications plans and, in doing so, strive to build substantial value for our shareholders. Accomplishments The last seven months have been highly productive. We have raised capital, presented new data and advanced the clinical programs for both products, as well as demonstrated dramatic yield improvements at our manufacturing facility. The key milestones we have hit during this active period are: Financing * Raised $17.9 million through the completion of a private placement in February/March and the exercise of warrants between June and August.
Multiple Sclerosis — NeuroVax(TM)
* Organized clinical investigators at sites in 12 European countries for patient enrollment to begin before year end for our 200-patient Phase IIb trial of NeuroVax(TM)
* Secured key partnerships with a leading MS clinical research organization (CRO) and outstanding MRI analysis facility to oversee and support our Phase IIb NeuroVax(TM) trial * Established a prestigious MS scientific advisory board composed of key opinion leaders who are now active in helping guide the development of NeuroVax(TM)
* Presented new Phase II data at the American Academy of Neurology (AAN) meeting demonstrating the ability of NeuroVax(TM) to restore MS patients’ FOXP3+ regulatory T-cell levels which are believed to help control disease progression
HIV/AIDS — IR103
* Completed the first stage of enrollment of anti-retroviral nave patients (55 new patients, 31 returning patients) in our Phase II trial of IR103 in Italy
* Announced approval to expand our Phase II trial of IR103 in Italy to include clinical sites in France as well as an additional 50 patients * Presented preliminary Phase II data at the ISHEID conference demonstrating IR103’s ability to enhance HIV-specific immune responses in drug naive patients
Tomorrow we will bring you and update on the manufacturing activities. We want to get you back up to speed on this company as we begin to release documents regarding valuations and important directions the company is taking.
REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
Forward Looking Statement and Safe Harbor: Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.
In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.
Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.